Clinical Trial Update: A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

View source ↗

Summary

A real-world observational study in U.S. urology clinics to examine how darolutamide and other androgen receptor pathway inhibitors are used and what outcomes o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Nubeqa (darolutamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms, Metastatic Hormone-Sensitive Prostate Cancer | Status: RECRUITING